[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autonomic-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autonomic-failure":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,49,73,99,125,148,169,192],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100422592","use-of-accelerometer-for-quantification-of-neurogenic-orthostatic-hypotension-symptoms-100422592",false,"NCT04782830","Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms","Inclusion Criteria:\n\n* Male and female subjects, age 40-80 years.\n* Possible or probable Multiple Systems Atrophy, Pure Autonomic Failure, or Parkinson's disease with neurogenic orthostatic hypotension.\n* Neurogenic orthostatic hypotension defined as a ≥ 30 mmHg decrease in systolic blood pressure within 3 minutes of standing associated with impaired autonomic reflexes determined by autonomic testing in the absence of other identifiable causes.\n* Patients on treatment for neurogenic orthostatic hypotension with either midodrine or atomoxetine, who have experienced some improvement in their orthostatic symptoms, but still remain symptomatic (Orthostatic hypotension symptom assessment \\[OHSA\\] score of 1 to 5 while on medication).\n* Patients who are able to stay with their caregiver during study participation.\n* Able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Bedridden, physically disabled, or unable to walk.\n* Patients with Orthostatic hypotension symptom assessment (OHSA) score ≥ 6, or orthostatic systolic blood pressure drop ≥ 30 mmHg on their regular treatment.\n* Patients taking more than one medication for the treatment of neurogenic orthostatic hypotension (concomitant use of pyridostigmine or fludrocortisone are accepted).\n* Pregnancy\n* Systemic illnesses known to produce autonomic neuropathy, including but not limited to diabetes mellitus, amyloidosis, monoclonal gammopathies, and autoimmune neuropathies.\n* Clinically unstable coronary artery disease (recurrent angina despite medical therapy), or major cardiovascular or neurological event in the past 6 months (myocardial infarction, stroke).\n* Concomitant use of anticoagulants.","ALL","40 Years","80 Years",{"count":19,"type":20},29,"ESTIMATED","INTERVENTIONAL",[23],"NA","The objective of this study is to find a more objective and accurate way to assess the efficacy of the treatment for neurogenic orthostatic hypotension. For this purpose, the investigators will use an activity monitor to determine the amount of time patients spend in the upright position (standing and walking; upright time) during 1 week of placebo (a pill with no active ingredients) and 1 week of their regular medication for orthostatic hypotension (midodrine or atomoxetine at their usual doses). Total upright time (i.e. tolerance to standing and walking) will be compared between placebo and active treatment to test the hypothesis that it can be used to assess the efficacy of the treatment for orthostatic hypotension and whether this outcome is superior to the assessment of symptoms using validated questionnaires.",[26,27,28,29,30],"Orthostatic; Hypotension, Neurogenic","Autonomic Failure","Pure Autonomic Failure","Multiple System Atrophy","Orthostatic; Hypotension, Parkinsonism",[32,33,34,35],"orthostatic hypotension","autonomic failure","accelerometer","orthostatic symptoms","RECRUITING","2026-06-29",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2021-02-05",{"date":44,"type":20},"2027-10-01",{"name":46,"class":47},"Vanderbilt University Medical Center","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":48},"100509079","co2-rebreathing-in-noh-a-proof-of-concept-pilot-study-100509079","NCT05908760","CO2 Rebreathing in nOH: A Proof-of-Concept Pilot Study","CO2 Rebreathing to Increase Blood Pressure in Neurogenic Orthostatic Hypotension: A Proof-of-Concept Pilot Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Male and Female\n* Physician diagnosis of Neurogenic Orthostatic Hypotension\n* Non-smokers.\n* Able and willing to provide informed consent.\n* Ability to travel to Libin Cardiovascular Institute Autonomic Testing Lab at the University of Calgary, Calgary, AB.\n\nExclusion Criteria:\n\n* Medical therapies or medications which could interfere with testing of autonomic function\n* Pregnant or breast-feeding females\n* Subjects with chronic heart failure or severe pulmonary disease who are unable to climb one flight of stairs due to shortness of breath.\n* Presence of failure of other organ systems or systemic illness that can affect autonomic function or the participant's ability to cooperate. These include dementia, alcohol and\u002For drug abuse, cerebrovascular disease, kidney or liver disease, surgical procedures where the nerves of the sympathetic nervous system have been cut.\n* Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies.","18 Years","100 Years",{"count":59,"type":20},28,[23],"Neurogenic orthostatic hypotension (nOH) is a chronic condition associated with increased cardiovascular risk and reduced quality of life. On standing, patients with nOH experience a large reduction in blood pressure (BP; at least ≥20\u002F10mmHg, but often much more), which is often accompanied by debilitating symptoms and syncope. A previous study (unpublished) showed that hypercapnia significantly increases standing BP in patients with nOH. Human bodies naturally produce and exhale CO2. Rebreathe devices offer a simple, cost-effective technology to increase arterial CO2. In brief, rebreathe devices work by capturing expired CO2, which is then re-inhaled. The net effect is a transient increase in CO2. A CO2 rebreathing device may offer a novel hemodynamic therapy for patients with nOH.\n\nThis is a pilot, proof-of-concept study to evaluate a CO2 rebreather to improve blood pressure and orthostatic tolerance in patients with nOH. The hypothesis is that a rebreather will increase CO2 sufficiently enough to improve BP in patients with nOH.\n\nMale and female patients (n=28) will be asked to complete two randomized 70° head-up tilt (HUT) tests breathing either room air or using a CO2 rebreather. Hemodynamics (BP, heart rate, stroke volume, brain blood flow) and orthostatic symptoms will be assessed throughout. Breath-by-breath data will include O2, CO2, respiration rate and tidal volume.\n\nThe primary outcome measure will be the magnitude of the BP response (ΔBP = HUT - Supine) during Room Air vs. Hypercapnia. The primary outcome will be compared between room air and hypercapnia using a paired t-test.",[63,27],"Neurogenic Orthostatic Hypotension","2026-04-29",{"date":66,"type":40},"2026-05-05",{"date":68,"type":40},"2024-07-30",{"date":70,"type":20},"2030-12-31",{"name":72,"class":47},"University of Calgary",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":48},"100476871","cpap-for-the-treatment-of-supine-hypertension-100476871","NCT05489575","CPAP for the Treatment of Supine Hypertension","Hemodynamic Effects of Positive Airway Pressure to Treat Supine Hypertension and Improve Neurogenic Orthostatic Hypotension","Inclusion Criteria:\n\n* Male and female subjects, age 40-80 years, with autonomic failure including pure autonomic failure, multiple system atrophy and Parkinson disease.\n* Neurogenic orthostatic hypotension, defined as a ≥20-mmHg decrease in systolic blood pressure within 3 minutes of standing associated with impaired autonomic reflexes determined by autonomic testing in the absence of other identifiable causes.\n* Nocturnal supine hypertension (nighttime systolic blood pressure ≥140 mmHg) during the overnight screening for supine hypertension.\n* Patients who are willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Patients with history of recent facial trauma or surgery or intolerance to CPAP or to the CPAP mask.\n* Patients who cannot tolerate the medication withdrawal, defined as those who are unable to stand for at least one minute or those with sustained supine blood pressure ≥180\u002F110 mmHg after the medication withdrawal period.\n* Bedridden patients or those who are unable to stand due to motor impairment or severe orthostatic hypotension.\n* Smokers, patients who are pregnant, or have clinically unstable coronary artery disease, or major cardiovascular or neurological event in the past 6 months; heart failure; and other factors which in the investigator's opinion would prevent the subject from completing the protocol including clinically significant abnormalities in clinical or laboratory testing.",{"count":81,"type":20},59,[23],"This study aims to learn about the effects of continuous positive airway pressure (CPAP) on people with autonomic failure and high blood pressure when lying down (supine hypertension) to determine if it can be used to treat their high blood pressure during the night. CPAP (a widely used treatment for sleep apnea) involves using a machine that blows air into a tube connected to a mask covering the nose, or nose and mouth, to apply a low air pressure in the airways.\n\nThe study includes 3-5 days spent in the Vanderbilt Clinical Research Center (CRC): at least one day of screening tests, followed by up to 3 study days. Subjects may be able to participate in daytime and\u002For overnight studies. The Daytime study consists of 2 study days: one with active CPAP and one with sham CPAP applied for up to 2 hours. The Overnight study consists of 3 study nights: one with active CPAP, one with sham CPAP, both applied for up to 9 hours and one night sleeping with the bed tilted head-up.",[27,28,29,85,86,63],"Parkinson Disease","Supine Hypertension",[88,89,90],"CPAP","Hypertension","Orthostatic hypotension","2026-03-31",{"date":93,"type":40},"2026-04-07",{"date":95,"type":40},"2022-06-23",{"date":97,"type":20},"2027-08-31",{"name":46,"class":47},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":15,"minAge":56,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":48},"100381425","phase-1-18ff-dopa-imaging-in-patients-with-autonomic-failure-100381425","NCT04246437","[18F]F-DOPA Imaging in Patients With Autonomic Failure","Inclusion Criteria:\n\n1. Patients with a diagnosis if pure autonomic failure\n2. Patients with autonomic failure and possible PD, MSA, or DLB\n3. Healthy adults aged 18 and above\n4. Clinical exam confirming clinical designation\n\nExclusion Criteria:\n\n* Subjects who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.), because such devices may be displaced or malfunction.\n* Subjects who have any type of ferromagnetic bioimplant that could potentially be displaced.\n* Subjects who have cerebral aneurysm clips.\n* Subjects who may have shrapnel imbedded in their bodies (such as from war wounds), metal workers and machinists (potential for metallic fragments in or near the eyes).\n* Subjects who are pregnant, because the effects of high field MRI on fetuses are not yet known.\n* Minors (younger than 18 years)\n\nAlso excluded are subjects incapable of giving informed written consent:\n\n* Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher.\n* Subjects who have limited mental ability to give informed consent, mentally retarded, altered mental status, mental disability, confusion, or psychiatric disorders.\n* Prisoners",true,{"count":107,"type":20},40,[109],"PHASE1","Alpha-synucleinopathies refer to age-related neurodegenerative and dementing disorders, characterized by the accumulation of alpha-synuclein in neurons and\u002For glia. The anatomical location of alpha-synuclein inclusions (Lewy Bodies) and the pattern of progressive neuronal death (e.g. caudal to rostral brainstem) give rise to distinct neurological phenotypes, including Parkinson's disease (PD), Multiple System Atrophy (MSA), Dementia with Lewy Bodies (DLB). Common to these disorders are the involvement of the central and peripheral autonomic nervous system, where Pure Autonomic Failure (PAF) is thought (a) to be restricted to the peripheral autonomic system, and (b) a clinical risk factor for the development of a central synucleinopathy, and (c) an ideal model to assess biomarkers that predict phenoconversion to PD, MSA, or DLB. Such biomarkers would aid in clinical trial inclusion criteria to ensure assessments of disease- modifying strategies to, delay, or halt, the neurodegenerative process. One of these biomarkers may be related to the neurotransmitter dopamine (DA) and related changes in the substantia nigra (SN) and brainstem. \\[18F\\]F-DOPA is a radiolabeled substrate for aromatic amino acid decarboxylase (AAADC), an enzyme involved in the production of dopamine. Use of this radiolabeled substrate in positron emission tomography (PET) may provide insight to changes in monoamine production and how they relate to specific phenoconversions in PAF patients. Overall, this study aims to identify changes in dopamine production in key regions including the SN, locus coeruleus, and brainstem to distinguish between patients with PD, MSA, and DLB, which may provide vital information to predict conversion from peripheral to central nervous system disease.",[27,28,85,29,112],"Dementia With Lewy Bodies",[114,115],"FDOPA","PET","2026-03-12",{"date":118,"type":40},"2026-03-16",{"date":120,"type":40},"2020-02-04",{"date":122,"type":20},"2027-02-01",{"name":124,"class":47},"Daniel Claassen",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":17,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":48},"100289072","overnight-trials-with-heat-stress-in-autonomic-failure-patients-with-supine-hypertension-100289072","NCT03042988","Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension","Overnight Trials to Compare the Effects of Controlled Heat Stress Versus Sham Control on Nocturnal Supine Hypertension in Autonomic Failure Patients","Inclusion Criteria:\n\n* Male and female patients, between 18-80 yrs., with primary autonomic failure (Parkinson Disease, Multiple System Atrophy, and Pure Autonomic Failure) and supine hypertension. Supine hypertension will be defined as SBP≥150 mmHg.\n* Patients able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Pregnancy\n* Significant cardiac, renal or hepatic illness, or with contraindications to administration of pressor agents or with other factors, which in the investigator's opinion would prevent the subject from completing the protocol including clinically significant abnormalities in clinical, mental or laboratory testing.",{"count":133,"type":20},20,[23],"Patients with autonomic failure are characterized by disabling orthostatic hypotension (low blood pressure on standing), and at least half of them also have high blood pressure while lying down (supine hypertension). Exposure to heat, such as in hot environments, often worsens their orthostatic hypotension. The causes of this are not fully understood. The purpose of this study is to evaluate whether applying local heat over the abdomen of patients with autonomic failure and supine hypertension during the night would decrease their nocturnal high blood pressure while lying down. This will help us better understand the mechanisms underlying this phenomenon, and may be of use in the treatment of supine hypertension.",[89,28,29,27],[138,33,139,32],"supine hypertension","heat stress","2026-01-14",{"date":142,"type":40},"2026-01-16",{"date":144,"type":40},"2017-01-30",{"date":146,"type":20},"2026-12-30",{"name":46,"class":47},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":48},"100401052","effect-of-raised-head-of-the-bed-on-lying-blood-pressure-in-autonomic-failure-100401052","NCT04502225","Effect of Raised Head of the Bed on Lying Blood Pressure in Autonomic Failure","Impact of Decreased Venous Return on Supine Blood Pressure","Inclusion Criteria:\n\n* Patients with autonomic failure and with supine hypertension from all races\n* Males and females, between 18 to 85 years\n\nExclusion Criteria:\n\n* All medical students\n* Pregnant women\n* High-risk patients (for example: heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction)\n* History of serious allergies or asthma.","85 Years",{"count":157,"type":20},44,[23],"Many persons with autonomic failure often have high blood pressure when lying down (supine hypertension). This study is exploring the impact of decreased venous return to the heart (achieved by raising the head of the bed) to lessen supine blood pressure. If decreased venous return to the heart is effective at lowering supine blood pressure, these approaches may be utilized to treat supine hypertension non-pharmacologically. Raising the head of the bed decreases the amount of blood returning to the heart due to the effects of gravity. In this case, the decreased blood return to the heart may decrease blood pressure.",[86,27],"2025-11-04",{"date":163,"type":40},"2025-11-06",{"date":165,"type":40},"2020-08-21",{"date":167,"type":20},"2026-12-31",{"name":46,"class":47},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":155,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":48},"100309761","treatment-of-supine-hypertension-in-autonomic-failure-cpap-100309761","NCT03312556","Treatment of Supine Hypertension in Autonomic Failure (CPAP)","Treatment of Supine Hypertension in Autonomic Failure With Continuous Positive Airway Pressure","Inclusion Criteria:\n\n* Patients with autonomic failure and with supine hypertension from all races\n\nExclusion Criteria:\n\n* All medical students\n* Pregnant women\n* High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction)\n* History of serious allergies or asthma.",{"count":177,"type":20},12,[23],"Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decreases blood pressure in autonomic failure patients with supine hypertension.",[86,27],[182,138,33,183,184,185],"hypertension","pure autonomic failure","multiple system atrophy","cpap",{"date":163,"type":40},{"date":188,"type":40},"2017-09-21",{"date":190,"type":20},"2026-12-21",{"name":46,"class":47},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":199,"targetDuration":4,"studyType":21,"phases":201,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":48},"100277879","phase-1-effects-of-midodrine-and-droxidopa-on-splanchnic-capacitance-in-autonomic-failure-100277879","NCT02897063","Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure","The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2","Inclusion Criteria:\n\n* Male and female subjects, age 40-80 years with possible or probable Multiple System Atrophy, Pure Autonomic Failure, or Parkinson disease, as defined by Consensus Criteria.\n* Neurogenic orthostatic hypotension defined as a ≥30-mmHg decrease in systolic blood pressure within 3 minutes of standing associated with impaired autonomic reflexes determined by autonomic testing in the absence of other identifiable causes.\n* Subjects able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Supine hypertension, defined as systolic blood pressure of ≥ 160 mmHg measured on two separate occasions.\n* Pregnancy.\n* Systemic illnesses known to produce autonomic neuropathy, including but not limited to diabetes mellitus, amyloidosis, monoclonal gammopathies, and autoimmune neuropathies.\n* History of known aortic aneurisms, thoracic, abdominal or pelvic surgery in the past 6 months.\n* Symptomatic abdominal or inguinal hernias.\n* Severe gastroesophageal reflux.\n* Recent fractures or fissures of ribs, thoracic or lumbar spine.\n* Medical devices implanted on the abdominal wall or abdomen that would interfere with the abdominal compression.\n* Intolerance to any increase in intraabdominal pressure.\n* Clinically unstable coronary artery disease or major cardiovascular or neurological event in the past 6 months, and other factors which in the investigator's opinion would prevent the subject from completing the protocol including clinically significant abnormalities in clinical, mental or laboratory testing.",{"count":200,"type":20},34,[109],"The purpose of this study is to learn more about the effects of midodrine and droxidopa, two medications used for the treatment of orthostatic hypotension (low blood pressure on standing), on the veins of the abdomen of patients with autonomic failure. The study will be conducted at Vanderbilt University Medical Center, and consists of 2 parts: a screening and 2 testing days. The total length of the study will be about 5 days. About 34 participants will be screened for the study.",[27,28,29,85,204],"Orthostatic Hypotension",[206,207,208],"midodrine","droxidopa","splanchnic circulation","2025-10-08",{"date":211,"type":40},"2025-10-14",{"date":213,"type":4},"2016-09",{"date":215,"type":20},"2026-12",{"name":46,"class":47}]